文献速递血栓与止血

接受免疫检查点抑制剂治疗患者的免疫性血小板减少症

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.
PubMed 文献 · Blood · 2026-01-01

本研究回顾了2016至2023年间在美国7大癌症中心29家医院启动ICI治疗的86 467例成人患者病历,免疫检查点抑制剂相关免疫性血小板减少症(ICI-ITP)发生率为0.25%(214例)。独立危险因素包括基线血小板计数较低、联合ICI治疗、IV期癌症及额外免疫相关不良事件。ICI-ITP及其严重程度与全因死亡率升高相关,重症ICI-ITP患者死亡风险约为无ICI-ITP患者的2.96倍(95%CI 2.14-4.08)。

要点

  • ICI-ITP发生率为0.25%(214/86 467),中位发生时间为ICI启动后8周(IQR 4-18)。
  • 独立危险因素包括基线血小板计数较低、联合ICI治疗、IV期癌症及额外免疫相关不良事件。
  • 重症ICI-ITP患者全因死亡风险约为无ICI-ITP患者的2.96倍(95%CI 2.14-4.08)。

核心结论

  • ICI-ITP是ICI治疗中罕见但具有临床意义的并发症,本研究据作者所知为首个大规模描述其危险因素和临床病程的研究,并强调及时识别和管理的重要性。

研究设计与样本

  • 回顾性病历审查,纳入2016至2023年间在美国7大癌症中心29家医院启动ICI治疗的86 467例成人患者,识别其中214例ICI-ITP患者。
  • 采用多变量逻辑回归识别危险因素,Cox模型评估ICI-ITP及其严重程度与死亡率的关联。

主要发现

  • 86 467例患者中ICI-ITP发生于214例(0.25%)。
  • 独立危险因素包括基线血小板计数较低、联合ICI治疗、IV期癌症及额外免疫相关不良事件。
  • ICI-ITP中位发生于ICI启动后8周(IQR 4-18),中位最低血小板计数为41×10^9/L(IQR 17×10^9/L至64×10^9/L)。
  • 治疗使用糖皮质激素(n=106[49.5%])、免疫球蛋白(n=39[18.2%])和血小板生成素受体激动剂(n=29[13.6%])。
  • 161例(75.2%)患者恢复,中位恢复时间2.3周(IQR 1.0-5.3);76例再次接受ICI治疗的患者中23例(30.3%)复发ICI-ITP。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitor-associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI therapy between 2016 and 2023 at 29 US hospitals across 7 major cancer centers to identify patients with ICI-ITP. Multivariable logistic regression was used to identify risk factors, and Cox modeling was performed to assess the association between ICI-ITP, its severity, and mortality. Among 86 467 patients, ICI-ITP occurred in 214 (0.25%). Independent risk factors included lower baseline platelet count, combination ICI therapy, stage IV cancer, and additional immune-related adverse events. ICI-ITP occurred at a median of 8 weeks (interquartile range [IQR], 4-18) after ICI initiation, with a median nadir platelet count of 41 × 109/L (IQR, 17 × 109/L to 64 × 109/L). Patients were treated with glucocorticoids (n = 106 [49.5%]), immune globulin (n = 39 [18.2%]), and thrombopoietin receptor agonists (n = 29 [13.6%]). Recovery occurred in 161 patients (75.2%) at a median of 2.3 weeks (IQR, 1.0-5.3). Of 76 patients rechallenged with ICIs, 23 (30.3%) developed recurrent ICI-ITP. ICI-ITP and its severity were associated with higher all-cause mortality, with a nearly threefold increase in risk among patients with severe ICI-ITP than those without ICI-ITP (adjusted hazard ratio, 2.96 [95% confidence interval, 2.14-4.08]). These findings establish ICI-ITP as a rare but clinically significant complication of ICI therapy, provide, to our knowledge, the first large-scale description of its risk factors and clinical course, and underscore the importance of timely recognition and management.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Leaf RK, Mones JV, Shenoy T, et al. Immune thrombocytopenia in patients treated with immune checkpoint inhibitors. Blood. 2026. PMID: 41359796. doi:10.1182/blood.2025031449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。